H-CYTE, Inc. (HCYT)
Stock Price: $0.0400 USD
-0.0060 (-13.04%)
Updated Jan 19, 2021 3:46 PM EST - Market closed
| Market Cap | 6.66M |
| Revenue (ttm) | 3.53M |
| Net Income (ttm) | -26.33M |
| Shares Out | 116.97M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $0.0400 |
| Previous Close | $0.0460 |
| Change ($) | -0.0060 |
| Change (%) | -13.04% |
| Day's Open | 0.0400 |
| Day's Range | 0.0311 - 0.0460 |
| Day's Volume | 94,977 |
| 52-Week Range | 0.006 - 0.196 |
News
There are no news available yet.
About HCYT
H-CYTE, a medical biosciences company, develops and implements various treatment options in regenerative medicine to treat chronic lung diseases. It engages in the development of L-CYTE-01 for the treatment of chronic obstructive pulmonary diseases. The company is headquartered in Tampa, Florida.
| Industry Medical Devices | |
| Stock Exchange OTCMKTS | Ticker Symbol HCYT |
Financial Performance
In 2019, H-CYTE, Inc.'s revenue was $8.35 million, an increase of 5.88% compared to the previous year's $7.88 million. Losses were -$29.81 million, 578.4% more than in 2018.